JRoon71
5 minutes ago
Kube, you're not wrong, and it is a dilemma.
It's true, I don't think Amarin has (or had) much of a choice in suspending marketing of Vascepa in the U.S. They may have been able to roll the dice and see how big they could grow the market, all while battling the generics in court, and